Tigo Expands TS4-A Platform with New Add-on UL-system-certified Rapid Shutdown Solution
18.3.2020 16:00:00 EET | Business Wire | Press release
Tigo Energy, Inc.®, pioneer of the smart modular Flex MLPE, today announced a new addition to the add-on TS4 Platform - the TS4-A-S. This add-on safety solution brings the solar market’s only module-level power electronic (MLPE) multivendor UL-system-certified solution for rapid shutdown. Tigo’s safety solution complies with NEC 2014, 2017, and 2020 with more than 100 inverters for residential, commercial & industrial, and utility customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005094/en/
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by Tigo's communication accessories. Production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. Now taking orders for the TS4-A-S worldwide. (Photo: Business Wire)
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by the Tigo Access Point (TAP) and the Cloud Connect Advanced (CCA). DC production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. This TS4-A-S launch accompanies the recently announced TS4-A-M (Monitoring Add-on) launch earlier this month. These units complete Tigo’s transition from the legacy TS4-R retrofit platform to the TS4-A add-on platform with mechanical upgrades, UHD-Core technology, expanded specifications to support PV modules up to 500W. To learn more, join Tigo's free online "Rapid Shutdown featuring the TS4-A-S & NEC 2020" webinar on Thursday, March 26th at 10am PT.
The highlights of the new TS4-A-S (Safety Add-on) with rapid shutdown include:
- Comply with NEC 2014, 2017, 2020 rapid shutdown requirements
- Choose compatibility from more than 100 UL-system-certified inverters
- Choose compatibility from any module up to 500W
- Manual or automatic shutdown in event of AC grid loss
- Automatic email or SMS alerts about faults or operational issues
- Protect PV system assets with full visibility of performance
- Lower O&M costs when identifying specific module problems
- Utilize module manufacturer warranties when tracking module failures
“Only inverters and rapid shutdown devices that have been UL-certified as a system are certified as safe. There’s one multivendor solution for residential C&I – and that’s Tigo,” says Danny Eizips, VP of Hardware Engineering at Tigo. “Others might not meet mandatory safety requirements, and therefore, cannot be trusted as safe when installed together in one PV system. We're working diligently to educate our partners and customers worldwide to know the difference for the safest solar experience.”
Tigo is now taking orders for the TS4-A-S worldwide. The last inventory of legacy TS4-R-S units may be shipped per the discretion of Tigo and Tigo’s distribution partners as the new TS4-A-S shipments are prepared. Both units are fully backward compatible. For price and delivery, consult your preferred solar distributor, call Tigo at +1.408.402.0802, email sales@tigoenergy.com, or visit www.tigoenergy.com.
About Tigo Energy, Inc.
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005094/en/
Contact information
Tiffany Douglass
408.402.0802 x 430
marketing@tigoenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom